Beta-lactam Resistant Pseudomonas aeruginosa Prediction Score

Notes

This model predicts the risk of resistance to antipseudomonal beta-lactams among respiratory and bloodstream isolates of Pseudomonas aeruginosa and other non-fermenting gram-negative bacilli (NFGN) such as Acinetobacter baumanii, etc.

It is particularly useful in critically-ill patients with risk of infections due to P. aeruginosa or NFGN in the respiratory tract (ventilator-associated pneumonia) or bloodstream (prolonged hospitalization or severely immune compromised hosts with qSOFA score ≥2)

Select All Applicable Risk Factors

Bronchiectasis/cystic fibrosis

Prior infections or colonization with beta-lactam resistant P. aeruginosa within past 12 months

Prior use of antipseudomonal beta-lactams for >48 hours within 3-30 days of index infection

Antipseudomonal beta-lactams include piperacillin-tazobactam, ceftazidime, cefepime, meropenem, and imipenem
Resistance to any of these agents confers beta-lactam resistant P. aeruginosa

More Information

References

Troficanto C, et al. ASM Microbe 2016; Boston, MA, USA (Abstract #3505)
Al-Jaghbeer MJ, et al. ASM Microbe 2017; New Orleans, LA, USA (Abstract #3309)